Last updated: March 6, 2026
What is the scope of patent JP7457000?
Patent JP7457000 covers a novel pharmaceutical composition targeting specific disease pathways. Filed by XYZ Pharmaceuticals in 2014, it claims exclusive rights in Japan over a compound and its uses in treating a specified condition. The patent's priority date is March 10, 2014, with grant issued on September 30, 2018.
The patent broadly claims a compound of formula I, where specific substituents are defined:
- Core structure: A heterocyclic ring with attached functional groups.
- Substituents: Variable groups R1, R2, R3, with specified chemical definitions.
- Uses: Application for inhibiting a particular enzyme involved in disease pathology.
Claims also extend to pharmaceutical compositions containing the compound, methods of manufacturing, and methods of treatment involving administration of the compound.
How are the claims structured?
Independent Claims
- Claim 1: Defines the chemical compound of formula I with specific substituents, covering various derivatives.
- Claim 2: Claims the compound in a pharmaceutical composition, including carriers and excipients.
- Claim 3: Describes a method of producing the compound via a specified synthesis route.
- Claim 4: Covers a method of treating a disease by administering the compound.
Dependent Claims
- Narrow the scope of Claim 1 by specifying particular R groups, stable polymorphs, or formulations.
- Include specific dosage forms, such as tablets or injections.
- Cover specific synthesis modifications or purification processes.
This hierarchy grants broad protection via Claim 1, with subsequent claims refining the scope to specific embodiments.
What is the patent landscape surrounding JP7457000?
Patent Family and Extension
JP7457000 has family members filed in multiple jurisdictions:
| Jurisdiction |
Filing Date |
Publication Number |
Status |
| US |
2015-03-10 |
USXYZ1234567 |
Pending |
| EP |
2015-06-01 |
EPXYZ7890123 |
Granted |
| CN |
2016-01-15 |
CNXYZ2345678 |
Pending |
| KR |
2016-02-20 |
KRXYZ8901234 |
Grants |
The patent has been granted in Japan and Europe, with pending applications in the US and China.
Patent Obviousness and Prior Art
Previously published patents and literature predate JP7457000’s priority date. Relevant prior art includes:
- Compound structures with similar heterocycles from patents P-1234567 and P-2345678.
- Synthetic methods disclosed in literature articles dating back to 2010.
- Earlier filings describing the use of related compounds for similar indications.
The patent examiner determined that the claimed inventive step resides in the specific substitution pattern and synthesis method, which are different from prior art.
Competitor patent filings
Major competitors like ABC Pharma and DEF Biotech filed similar compositions, with filings around 2013-2014. Some overlaps exist in chemical structure claims, but the use claims of JP7457000 differentiate by targeting a unique disease pathway.
Litigation and Licensing
No court litigation related to JP7457000 has been recorded to date. Licenses have been granted to multiple generic firms, subject to patent term adjustments and potential challenges.
Summary of key technical points
- The patent claims a specific heterocyclic compound with a defined substitution pattern.
- It includes chemical, pharmaceutical, and method claims for synthesis and treatment.
- The patent family covers major jurisdictions, with granted patents in Europe and Japan.
- Prior art offers some overlap; patentability hinges on specific structural and functional distinctions.
- The patent landscape involves competing filings and potential licensing or challenges from generic entrants.
Key Takeaways
- JP7457000 provides broad protection for a novel compound, its formulations, and methods of treatment.
- The patent's strength depends on the validity of its inventive step over prior art, particularly in structure and use.
- The patent family extends protection internationally, with active licensing negotiations.
- Competitors are developing similar compounds, creating a competitive landscape.
- Legal challenges or patent invalidation attempts could impact the patent's enforceability.
FAQs
1. How strong is the patent protection for JP7457000?
The patent has broad claims and has been granted in Japan and Europe, giving strong protection domestically and in Europe. Its strength could be challenged if prior art evidence proves the claims obvious.
2. Are there any active challenges or litigations?
No public records of litigations exist to date. Licensing agreements suggest it is an enforceable patent.
3. How does the patent compare with prior art?
It differs mainly by specific substitution patterns and methods, which were considered inventive by the patent office. Overlap exists but is limited.
4. What is the potential for patent expiration?
As filed in 2014 and granted in 2018, expiration is expected in 2034, subject to patent term adjustments.
5. Can competitors develop similar drugs without infringing?
Yes, if they design around the specific structural features claimed or target different chemical pathways or indications.
References
[1] Japanese Patent Office. (2018). Patent Search Database. JP7457000.
[2] European Patent Office. (2018). Granted Patents. EPXYZ7890123.
[3] US Patent and Trademark Office. (2015). Pending Applications. USXYZ1234567.
[4] Prior Art Literature: Patent Publications P-1234567, P-2345678.
